Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease

FASEB Journal

Volumn 29, Issue 2, 2015, Pages 589-596

  Kapogiannis, Dimitrios ^a   Boxer, Adam ^b   Schwartz, Janice B ^b,c   Abner, Erin L ^d   Biragyn, Arya ^a   Masharani, Umesh ^c   Frassetto, Lynda ^c   Petersen, Ronald C ^e   Miller, Bruce L ^b   Goetzl, Edward J ^a,b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Jewish Home of San Francisco   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Dementia; Insulin resistance; Senescence

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; INSULIN RECEPTOR SUBSTRATE 1; MEMANTINE; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE 1; NERVE CELL ADHESION MOLECULE L1; UNCLASSIFIED DRUG; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; GLUCOSE TOLERANCE; HUMAN; IMMUNOADSORPTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CASE CONTROL STUDY; COGNITIVE DEFECT; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOSOMES; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION REGULATION; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHOSPHORYLATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924870696     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-262048     Document Type: Article

References (39)

1. Cersosimo, E., and DeFronzo, R. A. (2006) Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 22, 423-436
2. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73-77
3. Yamada, M., Ohnishi, H., Sano, Si., Nakatani, A., Ikeuchi, T., and Hatanaka, H. (1997) Insulin receptor substrate (IRS)-1 and IRS-2 are tyrosine-phosphorylated and associated with phosphatidylinositol 3-kinase in response to brain-derived neurotrophic factor in cultured cerebral cortical neurons. J. Biol. Chem. 272, 30334-30339
4. Dhe-Paganon, S., Ottinger, E. A., Nolte, R. T., Eck, M. J., and Shoelson, S. E. (1999) Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1. Proc. Natl. Acad. Sci. USA 96, 8378-8383
5. Amoui, M., Craddock, B. P., and Miller, W. T. (2001) Differential phosphorylation of IRS-1 by insulin and insulin-like growth factor I receptors in Chinese hamster ovary cells. J. Endocrinol. 171, 153-162
6. Gual, P., Le Marchand-Brustel, Y., and Tanti, J. F. (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87, 99-109
7. Goldstein, B. J., Bittner-Kowalczyk, A., White, M. F., and Harbeck, M. (2000) Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J. Biol. Chem. 275, 4283-4289
8. Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., and White, M. F. (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277, 1531-1537
9. Carlson, C. J., White, M. F., and Rondinone, C. M. (2004) Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem. Biophys. Res. Commun. 316, 533-539
10. Yi, Z., Langlais, P., De Filippis, E. A., Luo, M., Flynn, C. R., Schroeder, S., Weintraub, S. T., Mapes, R., and Mandarino, L. J. (2007) Global assessment of regulation of phosphorylation of insulin receptor substrate-1 by insulin in vivo in human muscle. Diabetes 56, 1508-1516
11. Herschkovitz, A., Liu, Y. F., Ilan, E., Ronen, D., Boura-Halfon, S., and Zick, Y. (2007) Common inhibitory serine sites phosphorylated by IRS-1 kinases, triggered by insulin and inducers of insulin resistance. J. Biol. Chem. 282, 18018-18027
12. Copps, K. D., and White, M. F. (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55, 2565-2582
13. Samuel, V. T., and Shulman, G. I. (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852-871
14. Hançer, N. J., Qiu, W., Cherella, C., Li, Y., Copps, K. D., and White, M. F. (2014) Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation. J. Biol. Chem. 289, 12467-12484
15. Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., and Craft, S. (2011) Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68, 51-57
16. Moloney, A. M., Griffin, R. J., Timmons, S., O'Connor, R., Ravid, R., and O'Neill, C. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243
17. Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., and Arnold, S. E. (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338
18. Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., and Goetzl, E. J. Identification of pre-clinical Alzheimer's disease by a profile of pathogenic proteins in neurallyderived blood exosomes: a case-control study. Alzheimers Dement. DOI:10.1016/j.jalz.2014.06.008
19. Petersen, R. C. (2004) Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194
20. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Jr., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292
21. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P. J., and Scheltens, P. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746
22. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M., and Trojanowski, J. Q.; Alzheimer's Disease Neuroimaging Initiative. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413
23. Irizarry, M. C., Webb, D. J., Bains, C., Barrett, S. J., Lai, R. Y., Laroche, J. P., Hosford, D., Maher-Edwards, G., and Weil, J. G. (2008) Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J. Alzheimers Dis. 14, 301-311
24. Cano, S. J., Posner, H. B., Moline, M. L., Hurt, S. W., Swartz, J., Hsu, T., and Hobart, J. C. (2010) The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J. Neurol. Neurosurg. Psychiatry 81, 1363-1368
25. Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G., Onyike, C. U., Hillis, A. E., Josephs, K. A., Boeve, B. F., Kertesz, A., Seeley, W. W., Rankin, K. P., Johnson, J. K., Gorno-Tempini, M. L., Rosen, H., Prioleau-Latham, C. E., Lee, A., Kipps, C. M., Lillo, P., Piguet, O., Rohrer, J. D., Rossor, M. N., Warren, J. D., Fox, N. C., Galasko, D., Salmon, D. P., Black, S. E., Mesulam, M., Weintraub, S., Dickerson, B. C., Diehl-Schmid, J., Pasquier, F., Deramecourt, V., Lebert, F., Pijnenburg, Y., Chow, T. W., Manes, F., Grafman, J., Cappa, S. F., Freedman, M., Grossman, M., and Miller, B.L. (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477
26. Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., Manes, F., Dronkers, N. F., Vandenberghe, R., Rascovsky, K., Patterson, K., Miller, B. L., Knopman, D. S., Hodges, J. R., Mesulam, M. M., and Grossman, M. (2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014
27. Schrijvers, E. M., Witteman, J. C., Sijbrands, E. J., Hofman, A., Koudstaal, P. J., and Breteler, M. M. (2010) Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 75, 1982-1987
28. Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., Haneuse, S., Craft, S., Montine, T. J., Kahn, S. E., McCormick, W., McCurry, S. M., Bowen, J. D., and Larson, E. B. (2013) Glucose levels and risk of dementia. N. Engl. J. Med. 369, 540-548
29. Qiu, C., Sigurdsson, S., Zhang, Q., Jonsdottir, M. K., Kjartansson, O., Eiriksdottir, G., Garcia, M.E., Harris, T.B., vanBuchem, M.A., Gudnason, V., and Launer, L. J. (2014) Diabetes, markers of brain pathology and cognitive function: the Age, Gene/Environment Susceptibility-Reykjavik Study. Ann. Neurol. 75, 138-146
30. Craft, S., and Watson, G. S. (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3, 169-178
31. Planel, E., Tatebayashi, Y., Miyasaka, T., Liu, L., Wang, L., Herman, M., Yu, W. H., Luchsinger, J. A., Wadzinski, B., Duff, K. E., and Takashima, A. (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J. Neurosci. 27, 13635-13648
32. Zhao, W. Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., and Klein, W. L. (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric abeta. J. Biol. Chem. 284, 18742-18753
33. Duarte, A. I., Moreira, P. I., and Oliveira, C. R. (2012) Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012, 384017
34. Neumann, K. F., Rojo, L., Navarrete, L. P., Farías, G., Reyes, P., and Maccioni, R. B. (2008) Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 5, 438-447
35. Schiöth, H.B., Craft, S., Brooks, S.J., Frey II, W.H., and Benedict, C. (2012) Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol. Neurobiol. 46, 4-10
36. Bosco, D., Fava, A., Plastino, M., Montalcini, T., and Pujia, A. (2011) Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 15, 1807-1821
37. Lucas, J. J., Hernández, F., Gómez-Ramos, P., Morán, M. A., Hen, R., and Avila, J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39
38. Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Küstermann, E., Arndt, S., Jacobs, A. H., Krone, W., Kahn, C. R., and Brüning, J. C. (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 101, 3100-3105
39. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96